RecruitingPhase 1NCT06904066
Rare condition
Multiple myeloma
575
studies recruiting now
as of 7 Sept 2026
4,021
studies registered in total
as of 7 Sept 2026
3
countries with a recruiting site
as of 7 Sept 2026
10 Jun 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 1 / Phase 2NCT06049290
A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
RecruitingPhase 2NCT07637578
A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
RecruitingNot applicableNCT06262789
RAT-HEMATO : Return to Work After Malignant Hemopathy
RecruitingEarly phase 1NCT07493135
A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 575 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Multiple myeloma study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Multiple myeloma
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the gene involved (CCND1).
Treatments being studied
39 approved treatments and 335 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Motixafortide Acetate (Aphexda)Approved: Elotuzumab (Empliciti)Approved: Denosumab (Jubbonti)Approved: Carmustine (Bicnu)Approved: Lenalidomide (Lenalidomide accord)Approved: Plerixafor (Mozobil)Approved: Panobinostat Lactate (Farydak)Approved: Panobinostat (Farydak)Approved: Belantamab Mafodotin (Blenrep)Approved: Elranatamab (Elrexfio)Approved: Melphalan (Alkeran)Approved: Talquetamab (Talvey)Approved: BortezomibApproved: Vincristine Sulfate (Leurocristine sulfate)Approved: Cyclophosphamide (Cyclophosphamide)Approved: Isatuximab (Sarclisa)Approved: Lenalidomide Hydrochloride Monohydrate (Lenalidomide krka (previously lenalidomide krka d.d. novo mesto))Approved: Ixazomib Citrate (Ninlaro)Approved: Thalidomide (Kevadon)Approved: Zoledronic Acid (Aclasta)Approved: Sirolimus (Fyarro)Approved: Carfilzomib (Kyprolis)Approved: Melphalan FlufenamideApproved: Dexamethasone (Aeroseb-dex)Approved: Melphalan Flufenamide Hydrochloride (Pepaxti)Approved: Interferon Alfa-2b (Intron a)Approved: Pomalidomide (Imnovid)Approved: Bortezomib D-Mannitol (Bortezomib accord)Approved: Doxorubicin Hydrochloride (Adriamycin)Approved: Ciltacabtagene Autoleucel (Carvykti)Approved: Hyaluronidase (Human Recombinant) (Cumulase)Approved: Teclistamab (Tecvayli)Approved: MotixafortideApproved: Selinexor (Nexpovio)Approved: Daratumumab (Daratumumab component of darzalex faspro)Approved: IxazomibApproved: LinvoseltamabApproved: Doxorubicin (Adriblastina)Approved: Idecabtagene Vicleucel (Abecma)
Phase 3Enalapril
Phase 3Plitidepsin
Phase 3Siltuximab (Sylvant)
Phase 3Ibandronic Acid
Phase 3Pamidronate Disodium (Aredia)
Phase 3Busulfan (Busilvex)
Phase 3Mezigdomide
Phase 3Tabalumab
+ 327 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).